Diagnostic tool to help identify which patients to treat.



The Japanese Ministry of Health, Labor and Welfare approves Myriad Genetics’ (NASDAQ:MYGN) BRACAnalysis Diagnostic System as a companion diagnostic with AstraZeneca (NYSE:AZN) and Merck’s (NYSE:MRK) PARP inhibitor LYNPARZA (olaparib) for patients with BRCA-mutated metastatic breast cancer.

LYNPARZA was approved in Japan in January for certain ovarian cancer patients. The application for breast cancer is under review.

Previously: AstraZeneca’s Lynparza OK’d in Japan for ovarian cancer; shares up 1% premarket (Jan. 19)